Comparative Pharmacology
Head-to-head clinical analysis: PROMACTA versus PROMACTA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMACTA versus PROMACTA KIT.
PROMACTA vs PROMACTA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thrombopoietin receptor agonist. Binds to and activates the thrombopoietin receptor (c-Mpl) on hematopoietic stem cells, megakaryocyte progenitors, and megakaryocytes, leading to increased platelet production.
Thrombopoietin receptor agonist; binds to and activates the thrombopoietin receptor (c-Mpl), leading to increased platelet production.
50 mg orally once daily; increase to 75 mg once daily if platelet count remains <50,000/µL after 2 weeks; maximum 75 mg/day
Eltrombopag 50 mg orally once daily, with or without food; for ITP or SAA, if no response after 2 weeks, increase to 75 mg once daily (max 75 mg/day). Take on empty stomach (at least 1 hour before or 2 hours after meals) and at least 4 hours after calcium-rich foods, antacids, or multivitamins.
None Documented
None Documented
Terminal elimination half-life is approximately 21–32 hours in healthy subjects; in ITP patients, half-life ranges 26–35 hours supporting once-daily dosing.
21-35 hours in ITP patients; 26-35 hours in healthy subjects
Primarily fecal (93%) with minimal renal excretion (<6%). Biliary excretion of unchanged drug and metabolites contributes to fecal elimination.
Fecal (59% unchanged, 20% as metabolites); renal (31%, <1% unchanged)
Category C
Category C
Thrombopoietin receptor agonist
Thrombopoietin receptor agonist